[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-001", "question": "A 27-year-old G1P0 at 9 weeks' gestation presents with intractable nausea and vomiting, 7-kg weight loss, new-onset jaundice, and confusion over 3 days. She has no prior liver disease or alcohol use. Vitals: T 37.2°C, HR 122, BP 100/62, RR 18, SpO2 98% RA. Exam: scleral icterus, moderate right upper quadrant tenderness without rebound, asterixis. Labs: Na 132, K 3.1, bicarbonate 19, creatinine 1.2 mg/dL (baseline 0.6), AST 545 U/L, ALT 510 U/L, ALP 225 U/L, total bilirubin 12.4 mg/dL (direct 8.1), INR 2.6, ammonia 102 µmol/L, β-hCG markedly elevated for gestational age, thyroid studies: TSH low, free T4 and T3 mildly elevated. Abdominal ultrasound: single live intrauterine pregnancy, normal hepatic and portal vasculature, no biliary dilation, mild fatty liver change. Viral hepatitis serologies and autoimmune markers are pending. She is receiving IV fluids and antiemetics but continues to deteriorate neurologically. Which of the following is the most appropriate immediate next management step?", "options": ["Administer high-dose IV methylprednisolone and defer pregnancy decisions until serologies return", "Urgently proceed with uterine evacuation and initiate N-acetylcysteine infusion", "Start high-dose IV thiamine and parenteral nutrition while continuing pregnancy", "List for emergent liver transplantation without altering pregnancy status", "Administer propylthiouracil and beta-blockers to treat probable gestational thyrotoxicosis and reassess"], "answer": "B", "answer_index": 1, "explanation": "This presentation is most consistent with hyperemesis gravidarum-associated acute liver failure with encephalopathy and coagulopathy; maternal survival takes precedence, and rapid uterine evacuation plus N-acetylcysteine offers the best chance to reverse fulminant hepatic injury. Steroids (A) address autoimmune hepatitis, which is unconfirmed and too slow. Thiamine and nutrition (C) are supportive but insufficient in fulminant failure with encephalopathy. Immediate transplantation listing (D) may be needed but should follow rapid removal of the precipitating factor. Treating mild gestational thyrotoxicosis alone (E) will not address the primary life-threatening hepatic process.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with severe hyperemesis gravidarum complicated by hepatic dysfunction (elevated LFTs, jaundice, coagulopathy), encephalopathy (confusion, asterixis), and acute kidney injury. The markedly elevated beta-hCG, low TSH, and elevated free T4/T3 suggest gestational thyrotoxicosis, which can exacerbate hyperemesis and contribute to liver dysfunction. However, the severity of her presentation, particularly the coagulopathy and encephalopathy, points towards a more critical underlying process.\n\nLet's analyze the options:\n\nA. Administering high-dose IV methylprednisolone is not indicated for the primary cause of her liver failure. While it might be considered for certain autoimmune conditions, the immediate concern is the acute deterioration. Deferring pregnancy decisions is not appropriate given the severity.\n\nB. Urgently proceeding with uterine evacuation is a critical step. In severe cases of hyperemesis gravidarum, especially when complicated by hepatic dysfunction and encephalopathy, evacuation of the molar or abnormal pregnancy can lead to rapid improvement by removing the source of the excessively high hCG. N-acetylcysteine is an antidote for acetaminophen overdose, which is not suggested here. However, the principle of removing the source of the problem is key. Given the markedly elevated beta-hCG, a molar pregnancy or other gestational trophoblastic disease should be strongly considered, and evacuation is the definitive treatment.\n\nC. While thiamine and parenteral nutrition are supportive measures for hyperemesis, they do not address the underlying cause of her severe liver failure and encephalopathy. Continuing the pregnancy without addressing the cause of her deterioration is not the most appropriate immediate step.\n\nD. Listing for emergent liver transplantation is a consideration for irreversible liver failure. However, the patient's condition might be reversible if the underlying cause is addressed. Uterine evacuation could potentially reverse the liver dysfunction if it's related to an abnormal pregnancy. Therefore, transplantation is premature without attempting less invasive interventions.\n\nE. While gestational thyrotoxicosis is present and needs management, it is unlikely to be the sole cause of such severe liver failure and encephalopathy. Treating the thyrotoxicosis alone without addressing the potential underlying cause of liver failure (e.g., abnormal pregnancy) would be insufficient.\n\nConsidering the constellation of symptoms, particularly the severe hyperemesis, hepatic dysfunction, encephalopathy, and markedly elevated beta-hCG, the most likely diagnosis is hyperemesis gravidarum complicated by an abnormal pregnancy (e.g., molar pregnancy) leading to severe hepatic and neurological compromise. Uterine evacuation is the most appropriate immediate step to remove the source of the elevated hCG and potentially reverse the systemic complications.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-002", "question": "A 63-year-old man with long-standing hypertension and ischemic cardiomyopathy (EF 30%) presents with acute right hemiplegia and aphasia 45 minutes after symptom onset. NIHSS is 18. Noncontrast CT head shows no hemorrhage. CT angiography shows left M1 occlusion with favorable collaterals; CT perfusion suggests a large salvageable penumbra. ECG shows sinus rhythm with frequent PVCs. High-sensitivity troponin is mildly elevated and flat on serial testing. You plan IV thrombolysis and urgent mechanical thrombectomy. Which of the following additional acute management steps is most appropriate?", "options": ["Initiate IV unfractionated heparin infusion before mechanical thrombectomy due to high cardioembolic risk", "Administer IV labetalol to reduce blood pressure to <140/90 mm Hg prior to thrombolysis", "Start high-dose statin and delay any antiplatelet therapy until 24 hours after thrombolysis", "Begin dual antiplatelet therapy with aspirin and clopidogrel immediately after thrombolysis", "Place an intra-aortic balloon pump preemptively to support cerebral perfusion during thrombectomy"], "answer": "C", "answer_index": 2, "explanation": "The correct step is to start high-intensity statin immediately and delay antiplatelets until 24 hours after thrombolysis and repeat imaging, per acute ischemic stroke guidelines. Heparin before thrombectomy (A) increases hemorrhagic risk with no proven benefit. Lowering BP below 140/90 (B) before tPA is too aggressive and can worsen cerebral perfusion; only treat if >185/110 to that threshold. Dual antiplatelets immediately after tPA (D) markedly increases hemorrhage risk. Intra-aortic balloon pump (E) has no role in this setting and carries procedural risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with an acute ischemic stroke with a large territory occlusion and a significant penumbra, making him a candidate for reperfusion therapies. The question asks for the most appropriate *additional* acute management step.\n\nLet's analyze the options:\n\nA. Initiate IV unfractionated heparin infusion before mechanical thrombectomy due to high cardioembolic risk. While cardioembolic stroke is a possibility given his ischemic cardiomyopathy and PVCs, initiating anticoagulation *before* mechanical thrombectomy in the setting of a large vessel occlusion is generally not recommended due to the risk of hemorrhagic transformation, especially if thrombolysis is also planned. Anticoagulation is typically considered after successful reperfusion or if there's a clear indication for it.\n\nB. Administer IV labetalol to reduce blood pressure to <140/90 mm Hg prior to thrombolysis. Blood pressure management is crucial in acute ischemic stroke. For patients receiving IV thrombolysis, blood pressure should be maintained below 185/110 mm Hg before administration and below 180/105 mm Hg during and for 24 hours after treatment. While the patient's blood pressure is not stated, if it is elevated, controlled reduction is important to minimize the risk of hemorrhage. Labetalol is a suitable agent for this purpose. The target of <140/90 mm Hg is more aggressive than typically required for thrombolysis alone, but it's a reasonable target to consider in the context of potential thrombectomy and to reduce the risk of hemorrhagic complications.\n\nC. Start high-dose statin and delay any antiplatelet therapy until 24 hours after thrombolysis. High-dose statin therapy is beneficial in acute ischemic stroke, but the timing of antiplatelet therapy is important. For patients undergoing mechanical thrombectomy, dual antiplatelet therapy (DAPT) is often initiated soon after reperfusion, especially if the stroke is not hemorrhagic. Delaying all antiplatelet therapy for 24 hours might not be optimal for preventing early reocclusion or further ischemic events.\n\nD. Begin dual antiplatelet therapy with aspirin and clopidogrel immediately after thrombolysis. DAPT is often used in the setting of mechanical thrombectomy, particularly for anterior circulation large vessel occlusions. However, initiating DAPT *immediately* after thrombolysis, especially before confirming the absence of hemorrhage and assessing the success of thrombectomy, carries a risk of increased bleeding. The decision to start DAPT and its timing is usually made in conjunction with the interventionalist and neurologist, often after reperfusion is achieved and hemorrhage is ruled out.\n\nE. Place an intra-aortic balloon pump preemptively to support cerebral perfusion during thrombectomy. An intra-aortic balloon pump (IABP) is not a standard intervention for supporting cerebral perfusion during mechanical thrombectomy for acute ischemic stroke. Its primary use is in managing hemodynamic instability in conditions like cardiogenic shock or severe aortic regurgitation.\n\nConsidering the options, managing blood pressure is a critical immediate step when reperfusion therapies are planned. Option B addresses this directly and aligns with guidelines for blood pressure management in patients receiving thrombolysis. While the specific blood pressure is not given, if it is elevated, controlling it is paramount. The target of <140/90 mm Hg is a reasonable goal to aim for to optimize outcomes and minimize complications, especially in the context of planned thrombectomy.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-003", "question": "A 34-year-old woman with SLE (malar rash, arthritis, class III lupus nephritis on biopsy) on mycophenolate and low-dose prednisone presents with 3 months of progressive exertional dyspnea and dry cough. She has no smoking history. Vitals: HR 96, BP 112/70, RR 18, SpO2 94% RA. Exam: fine bibasilar crackles, no peripheral edema. Labs: creatinine 1.0 mg/dL, ANA 1:640 homogeneous, anti-dsDNA mildly elevated, complements low, ESR 18 mm/hr, CRP 2 mg/L. PFTs: FVC 65% predicted, FEV1/FVC 0.82, DLCO 40% predicted. HRCT: diffuse ground-glass opacities with scattered areas of consolidation and traction bronchiectasis, predominantly in lower lobes, no honeycombing. BAL: lymphocytic predominance, cultures negative. Echocardiogram: normal LV function, PASP 30 mm Hg. Which of the following is the most appropriate next step in management?", "options": ["Escalate mycophenolate dose and add high-dose oral prednisone without further diagnostics", "Switch mycophenolate to cyclophosphamide and simultaneously list for lung transplantation", "Perform surgical lung biopsy to distinguish organizing pneumonia from NSIP", "Add rituximab while continuing mycophenolate at the same dose", "Initiate nintedanib in addition to current immunosuppression for progressive fibrosing ILD"], "answer": "E", "answer_index": 4, "explanation": "This is SLE-associated progressive fibrosing interstitial lung disease with traction bronchiectasis and physiologic restriction despite immunosuppression; nintedanib has evidence for slowing decline in progressive fibrosing ILDs, including CTD-ILD. Blind escalation of steroids/mycophenolate (A) risks toxicity without clear additional benefit. Routine upfront lung transplant listing (B) is premature. Lung biopsy (C) is high risk and unlikely to alter management given established CTD-ILD pattern. Rituximab (D) can be considered, but antifibrotic therapy specifically targets the progressive fibrosing phenotype and is strongly indicated here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with progressive dyspnea, dry cough, and findings suggestive of interstitial lung disease (ILD) in the context of SLE. The PFTs show a restrictive pattern (reduced FVC) with significantly impaired gas exchange (low DLCO). The HRCT findings of ground-glass opacities, consolidation, and traction bronchiectasis, predominantly in the lower lobes, are consistent with an active inflammatory process and early fibrosis. The BAL showing lymphocytic predominance further supports an inflammatory etiology.\n\nLet's analyze the options:\n\nA. Escalate mycophenolate dose and add high-dose oral prednisone without further diagnostics: While increasing immunosuppression might be considered, the current presentation suggests a potentially fibrotic process, and simply escalating current therapy without a definitive diagnosis or assessment of response might not be the most appropriate next step. High-dose steroids can have significant side effects.\n\nB. Switch mycophenolate to cyclophosphamide and simultaneously list for lung transplantation: Cyclophosphamide is a potent immunosuppressant, but its use is typically reserved for more severe or refractory lupus manifestations. Listing for lung transplantation is a drastic measure and premature without a clear diagnosis and trial of medical therapy.\n\nC. Perform surgical lung biopsy to distinguish organizing pneumonia from NSIP: The HRCT findings are suggestive of an interstitial pneumonia. Differentiating between organizing pneumonia (OP) and non-specific interstitial pneumonia (NSIP) is crucial as their management and prognosis can differ. A surgical lung biopsy provides the most definitive histological diagnosis, which is essential for guiding therapy in complex ILD cases, especially when the etiology is unclear and the disease is progressive.\n\nD. Add rituximab while continuing mycophenolate at the same dose: Rituximab is effective in certain SLE manifestations, particularly B-cell mediated ones. However, its role in lupus-associated ILD is less established compared to other immunosuppressants, and it might not be the first-line agent for this specific presentation without a clearer indication of B-cell hyperactivity driving the lung disease.\n\nE. Initiate nintedanib in addition to current immunosuppression for progressive fibrosing ILD: Nintedanib is an anti-fibrotic agent used for progressive fibrosing ILDs. While the HRCT shows some traction bronchiectasis suggestive of fibrosis, the presence of significant ground-glass opacities and consolidation indicates an active inflammatory component. Treating this primarily as a fibrotic process with nintedanib without addressing the underlying inflammation and obtaining a definitive diagnosis might not be optimal. Furthermore, the diagnosis of progressive fibrosing ILD needs to be established.\n\nGiven the progressive nature of the symptoms, the restrictive PFTs with impaired DLCO, and the HRCT findings, a definitive diagnosis of the underlying interstitial lung disease is paramount to guide appropriate treatment. Surgical lung biopsy is the gold standard for differentiating between various types of ILD, such as organizing pneumonia and NSIP, which have different treatment approaches. This distinction is critical for optimizing management and prognosis.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-004", "question": "A 51-year-old woman with poorly controlled type 2 diabetes and prior pelvic radiation for cervical cancer presents with 5 days of fever, worsening lower abdominal pain, and foul vaginal discharge. She is hypotensive and tachycardic. Exam: diffuse lower abdominal tenderness with guarding, necrotic friable tissue at the posterior vaginal fornix with gas bubbles and crepitus extending toward the rectovaginal septum. Labs: WBC 19,000/µL, lactate 4.5 mmol/L, creatinine 2.1 mg/dL. CT abdomen/pelvis with contrast: extensive gas in the pelvis tracking along fascial planes into the perineum, no discrete drainable collection, suspected uterine and vaginal wall necrosis. Blood cultures are drawn, and broad-spectrum IV antibiotics and aggressive fluids are started. Which is the most appropriate next step?", "options": ["Urgent total abdominal hysterectomy with wide radical debridement of necrotic pelvic and perineal tissue", "Percutaneous CT-guided drainage of gas-containing pelvic spaces plus continued maximal antibiotics", "Hyperbaric oxygen therapy as a temporizing measure before any surgical intervention", "Emergent exploratory laparotomy limited to diagnostic assessment and peritoneal lavage", "Conservative management with antibiotics and close ICU monitoring to avoid worsening radiation injury"], "answer": "A", "answer_index": 0, "explanation": "The clinical picture is necrotizing pelvic soft tissue infection (type I Fournier-like process) involving uterus and vagina in a radiated field, requiring immediate radical surgical debridement including hysterectomy. Percutaneous drainage (B) is inadequate for necrotizing fasciitis. Hyperbaric oxygen (C) may be adjunctive but never replaces urgent debridement. Exploratory laparotomy without aggressive debridement (D) fails to control source. Conservative management (E) carries an almost universally fatal risk in necrotizing infections.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with signs and symptoms highly suggestive of necrotizing fasciitis of the pelvic and perineal region, likely originating from the vagina, complicated by sepsis (hypotension, tachycardia, elevated WBC, elevated lactate, elevated creatinine). The CT findings of extensive gas in the pelvis tracking along fascial planes and suspected uterine and vaginal wall necrosis further support this diagnosis. Necrotizing fasciitis is a surgical emergency requiring aggressive debridement.\n\nOption A: Urgent total abdominal hysterectomy with wide radical debridement of necrotic pelvic and perineal tissue is the most appropriate next step. This addresses the source of infection and removes the necrotic, non-viable tissue, which is crucial for controlling the spread of infection and improving the patient's chances of survival. The prior pelvic radiation may have contributed to tissue fragility and increased susceptibility to infection, but the primary management of necrotizing fasciitis is surgical.\n\nOption B: Percutaneous drainage is unlikely to be effective in necrotizing fasciitis, which involves diffuse fascial plane involvement rather than a discrete collection.\n\nOption C: Hyperbaric oxygen therapy can be an adjunct treatment for certain types of infections, but it is not the primary or most appropriate next step in the management of rapidly progressing necrotizing fasciitis. Surgical debridement is paramount.\n\nOption D: While emergent exploratory laparotomy is indicated, limiting it to diagnostic assessment and peritoneal lavage would be insufficient. The necrotic tissue needs to be debrided.\n\nOption E: Conservative management with antibiotics and monitoring is inappropriate given the patient's hemodynamic instability and the extent of suspected tissue necrosis. This condition is life-threatening and requires immediate surgical intervention.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-005", "question": "A 76-year-old man with permanent atrial fibrillation on apixaban, CKD stage 3b, and prior TIA undergoes TAVR for symptomatic severe aortic stenosis. Preprocedure echo: EF 55%, no intracardiac thrombus, moderate MAC, mild-moderate MR. Postprocedure, he develops acute severe dyspnea and hypotension 2 hours later. Echo: hyperdynamic LV with near-complete mid-cavity obliteration in systole, peak LVOT gradient 80 mm Hg, systolic anterior motion (SAM) of the mitral valve, severe MR, intact TAVR function. Which of the following is the most appropriate immediate management?", "options": ["Start high-dose IV furosemide and nitroprusside to rapidly reduce preload and afterload", "Administer aggressive IV crystalloids and start a phenylephrine infusion while reducing inotropes", "Urgently return to the cath lab for balloon post-dilatation of the TAVR prosthesis", "Begin IV milrinone infusion to augment contractility and improve forward flow", "Perform emergent surgical myectomy with mitral valve repair"], "answer": "B", "answer_index": 1, "explanation": "This is dynamic LVOT obstruction with SAM and severe MR precipitated by TAVR and low preload; management mirrors hypertrophic obstructive physiology-volume expansion and pure alpha-agonist (phenylephrine) to increase afterload while avoiding inotropes. Diuresis and vasodilators (A) and inotropes (D) worsen obstruction. Post-dilatation of the valve (C) is not indicated as prosthetic function is normal. Emergent surgery (E) is reserved for refractory cases after optimal medical hemodynamic management has failed.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with acute severe dyspnea and hypotension post-TAVR, with echocardiographic findings highly suggestive of severe systolic anterior motion (SAM) of the mitral valve leading to left ventricular outflow tract (LVOT) obstruction and severe mitral regurgitation (MR). The hyperdynamic LV with mid-cavity obliteration and high LVOT gradient are classic signs of SAM. This obstruction impedes forward flow, causing hypotension and pulmonary congestion (leading to dyspnea).\n\nLet's analyze the options:\n\nA. Starting high-dose IV furosemide and nitroprusside would further reduce preload and afterload. While reducing afterload might slightly decrease the LVOT gradient, reducing preload in the setting of severe LVOT obstruction and hypotension is dangerous as it can worsen the gradient and further compromise cardiac output.\n\nB. Administering aggressive IV crystalloids would increase preload. In the context of LVOT obstruction, increased preload can worsen the SAM and the LVOT gradient, potentially exacerbating the hypotension. Starting phenylephrine, a pure alpha-agonist, would increase systemic vascular resistance and afterload. While this might increase diastolic pressure and coronary perfusion, it could also worsen the LVOT gradient by increasing the pressure gradient across the obstruction. Reducing inotropes is appropriate if the patient was on them, but the primary issue is the obstruction.\n\nC. Urgently returning to the cath lab for balloon post-dilatation of the TAVR prosthesis is not the primary treatment for SAM. Balloon post-dilatation is used to address issues with the TAVR prosthesis itself, such as paravalvular leak or stenosis, not dynamic LVOT obstruction caused by SAM.\n\nD. Beginning an IV milrinone infusion would augment contractility and potentially improve forward flow. However, milrinone is a phosphodiesterase inhibitor that also causes vasodilation. The vasodilation can reduce afterload, which might be beneficial, but the increase in contractility can also worsen SAM. In the setting of severe LVOT obstruction, increasing contractility can worsen the dynamic obstruction.\n\nE. Performing emergent surgical myectomy with mitral valve repair is the definitive treatment for severe, symptomatic SAM with significant MR and LVOT obstruction that is refractory to medical management. In this case, the SAM is severe and causing hemodynamic instability. While medical management is attempted first, if it fails or is insufficient, surgical intervention is indicated. Given the severity of the symptoms and the echocardiographic findings, this is the most appropriate definitive management if medical measures are not rapidly effective. However, the question asks for the *most appropriate immediate management*. In the immediate setting, before surgery, the goal is to reduce the LVOT gradient and improve forward flow.\n\nRevisiting the options with a focus on immediate management: The core problem is the dynamic LVOT obstruction. The goal is to reduce the gradient. This is typically achieved by reducing contractility and increasing preload and afterload.\n\nLet's re-evaluate option B. Aggressive IV crystalloids to increase preload and phenylephrine to increase afterload are the cornerstones of medical management for obstructive SAM. Increasing preload can \"push\" the septum away from the anterior mitral leaflet, and increasing afterload can reduce the pressure gradient across the LVOT. Reducing inotropes is also crucial.\n\nConsidering the options again, the most appropriate *immediate* management for obstructive SAM causing hemodynamic instability is to increase preload and afterload while reducing contractility. Option B directly addresses this. While surgical myectomy is the definitive solution, it's not the immediate first step in management.\n\nLet's consider the typical management of obstructive SAM post-TAVR. The primary goal is to reduce the LVOT gradient. This is achieved by:\n1. Reducing contractility (beta-blockers, avoid inotropes).\n2. Increasing preload (IV fluids).\n3. Increasing afterload (vasopressors like phenylephrine).\n\nOption B aligns with these principles.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-006", "question": "A 42-year-old man who injects drugs presents with 10 days of fever, severe back pain, and new right leg weakness. Vitals: T 38.8°C, HR 108, BP 122/74. Exam: midline lumbar tenderness, right leg 3/5 strength with hyperreflexia, left leg 5/5, intact sensation, no bowel/bladder symptoms. Labs: WBC 15,000/µL, ESR 96 mm/hr, CRP 120 mg/L. Blood cultures: MRSA in 2/2 sets. MRI lumbar spine with contrast: dorsal epidural collection L2-L4 with significant canal compromise and enhancement consistent with epidural abscess, plus adjacent vertebral osteomyelitis; no discrete psoas abscess. He is started on IV vancomycin. Neurosurgery feels surgery is high risk due to severe cardiomyopathy (EF 20%) and active drug use, recommending medical therapy unless deterioration. What is the most appropriate next step?", "options": ["Continue IV vancomycin alone with close neurologic monitoring for at least 6 weeks", "Add rifampin to vancomycin to enhance penetration into epidural space and bone", "Perform urgent surgical decompression and drainage despite high perioperative risk", "Switch to daptomycin plus ceftaroline to provide broader MRSA coverage", "Place percutaneous CT-guided drain into the epidural collection to avoid open surgery"], "answer": "C", "answer_index": 2, "explanation": "He has spinal epidural abscess with evolving motor deficit and significant canal compromise; urgent surgical decompression and drainage is indicated despite elevated operative risk, as delay risks permanent paralysis. Medical therapy alone (A, B, D) is inadequate once neurologic deficits are present. Percutaneous drainage (E) is not appropriate for epidural abscess causing cord compression, as it rarely achieves effective decompression or safe access to the epidural space.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has a large epidural abscess with spinal cord compression, vertebral osteomyelitis, and neurological deficits (right leg weakness). While surgical decompression is generally the gold standard for spinal epidural abscesses causing significant neurological compromise, the patient has severe comorbidities (cardiomyopathy with EF 20%) and active drug use, making surgery high risk.\n\nThe question asks for the *most appropriate next step* given the current situation.\n\n*   **A. Continue IV vancomycin alone with close neurologic monitoring for at least 6 weeks:** While vancomycin is appropriate for MRSA, it may not provide optimal penetration into the epidural space and bone, especially in the presence of a large abscess. Close monitoring is essential, but this option might be insufficient without adjunctive therapy or consideration of other treatment modalities.\n\n*   **B. Add rifampin to vancomycin to enhance penetration into epidural space and bone:** Rifampin is known to penetrate well into bone and abscesses and has synergistic activity with vancomycin against MRSA. This combination is often used for osteomyelitis and complicated MRSA infections, including epidural abscesses, especially when surgical intervention is contraindicated or high risk. This addresses the need for better penetration and potentially more effective medical management.\n\n*   **C. Perform urgent surgical decompression and drainage despite high perioperative risk:** While surgery is often preferred, the prompt explicitly states neurosurgery feels surgery is high risk due to severe cardiomyopathy and active drug use, recommending medical therapy unless deterioration. Therefore, this is not the *most appropriate next step* given the current recommendation.\n\n*   **D. Switch to daptomycin plus ceftaroline to provide broader MRSA coverage:** Vancomycin is already effective against MRSA. While daptomycin and ceftaroline are options for MRSA, switching from vancomycin without clear evidence of resistance or failure is not the immediate priority. The issue is more about penetration and adjunctive therapy for a complex infection.\n\n*   **E. Place percutaneous CT-guided drain into the epidural collection to avoid open surgery:** Percutaneous drainage is sometimes used for abscesses, but for a large epidural abscess causing significant spinal cord compression, it is often less effective than surgical decompression in relieving pressure and may not adequately drain the entire collection. Given the severity of canal compromise, this is unlikely to be the best option.\n\nConsidering the high risk of surgery and the need for effective medical management of a deep-seated MRSA infection involving bone and epidural space, adding rifampin to vancomycin is a well-established strategy to improve treatment outcomes in such cases.\n\nThe answer is B"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-007", "question": "A 31-year-old woman presents with severe headaches, transient visual obscurations, and pulsatile tinnitus 6 months postpartum. She has gained 20 kg during and after pregnancy. BMI is 38 kg/m². Exam: bilateral papilledema, full strength, no focal deficits. MRI brain with and without contrast is normal. MRV shows smooth tapering and non-visualization of the terminal right transverse sinus with small caliber sigmoid sinus and jugular bulb; the left transverse sinus is dominant and widely patent. Lumbar puncture: opening pressure 34 cm H₂O, normal CSF studies. She is started on acetazolamide and advised weight loss but continues to have progressive visual field loss on serial perimetry over 8 weeks. What is the most appropriate next step in management?", "options": ["Place a ventriculoperitoneal shunt to lower intracranial pressure", "Perform right transverse sinus stenting across the narrowed segment", "Initiate high-dose oral topiramate instead of acetazolamide", "Perform optic nerve sheath fenestration to protect vision", "Start therapeutic anticoagulation for presumed chronic venous sinus thrombosis"], "answer": "D", "answer_index": 3, "explanation": "The patient has idiopathic intracranial hypertension with rapidly progressive visual loss despite maximal medical therapy; optic nerve sheath fenestration is the preferred intervention to promptly protect vision. VP shunting (A) is an option but has higher long-term failure and complication rates and is usually considered after or when ONSF is not feasible. Transverse sinus stenting (B) is usually reserved for documented significant pressure gradients and bilateral or dominant-sided stenosis; here the right sinus is small and nondominant. Topiramate (C) is an adjunct but insufficient alone given progressive visual decline. Anticoagulation (E) is not indicated without imaging evidence of thrombosis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symptoms and signs highly suggestive of idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri. Key features include severe headaches, transient visual obscurations, pulsatile tinnitus, papilledema, obesity (BMI 38), and elevated opening pressure on lumbar puncture (34 cm H₂O). The MRV findings of smooth tapering and non-visualization of the terminal right transverse sinus with a small caliber sigmoid sinus and jugular bulb, along with a dominant left transverse sinus, are consistent with venous sinus stenosis, a common underlying cause of IIH.\n\nThe patient has failed medical management with acetazolamide and weight loss, as evidenced by progressive visual field loss over 8 weeks. This indicates a need for more aggressive intervention to prevent irreversible vision loss.\n\nLet's evaluate the options:\n\nA. Place a ventriculoperitoneal shunt to lower intracranial pressure: While shunting can lower ICP, it is generally considered a less preferred option for IIH compared to addressing the underlying venous stenosis, especially when there are no signs of hydrocephalus. It also carries risks of shunt malfunction and infection.\n\nB. Perform right transverse sinus stenting across the narrowed segment: Given the MRV findings of significant venous sinus stenosis contributing to elevated ICP and the failure of medical management, endovascular stenting of the stenotic segment is a highly appropriate next step. This aims to improve venous outflow and reduce intracranial pressure, thereby protecting vision.\n\nC. Initiate high-dose oral topiramate instead of acetazolamide: Topiramate is another medication used for IIH, but if acetazolamide has failed, switching to another medical agent might not be sufficient, especially with progressive visual loss. Furthermore, the underlying venous stenosis is a mechanical issue that medication alone may not fully address.\n\nD. Perform optic nerve sheath fenestration to protect vision: Optic nerve sheath fenestration is a surgical procedure to relieve pressure on the optic nerve and is considered when vision loss is imminent and other treatments have failed or are not feasible. However, it addresses the symptom (optic nerve compression) rather than the underlying cause (elevated ICP due to venous stenosis). Stenting the venous sinus directly addresses the cause.\n\nE. Start therapeutic anticoagulation for presumed chronic venous sinus thrombosis: The MRV shows stenosis, not frank thrombosis. While venous sinus thrombosis can cause IIH, the description of \"smooth tapering and non-visualization\" is more indicative of stenosis than a complete clot. Anticoagulation would be inappropriate without clear evidence of thrombosis and carries bleeding risks.\n\nConsidering the progressive visual field loss despite medical management and the identified venous sinus stenosis, endovascular stenting of the narrowed transverse sinus is the most appropriate next step to address the underlying pathology and prevent further vision loss.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-008", "question": "A 29-year-old woman with a history of two early first-trimester miscarriages and one unexplained fetal demise at 28 weeks presents for preconception counseling. She has livedo reticularis and episodes of digital ischemia in cold weather. Labs: platelets 110,000/µL, hemoglobin 11.5 g/dL, creatinine 0.9 mg/dL. Coagulation profile is normal. aPTT is mildly prolonged. Lupus anticoagulant is repeatedly positive; anticardiolipin IgG and anti-β2-glycoprotein I IgG are high-titer on two occasions 12 weeks apart. She has no personal history of venous or arterial thrombosis. Which of the following is the most appropriate pregnancy management plan?", "options": ["Low-dose aspirin alone starting preconception, escalate to prophylactic LMWH only if thrombosis occurs", "Therapeutic-dose LMWH plus low-dose aspirin starting at positive pregnancy test and continuing 6 weeks postpartum", "Prophylactic-dose LMWH plus low-dose aspirin starting at conception and stopping at delivery", "Low-dose aspirin only during pregnancy, with postpartum prophylactic LMWH for 6 weeks", "No anticoagulation unless she develops hypertensive disorders of pregnancy"], "answer": "B", "answer_index": 1, "explanation": "She meets criteria for high-risk obstetric antiphospholipid syndrome with recurrent pregnancy loss and triple-positive aPL; therapeutic-dose LMWH plus low-dose aspirin throughout pregnancy and 6 weeks postpartum provides optimal maternal and fetal protection. Aspirin alone (A, D, E) is inadequate in high-risk APS. Prophylactic-dose LMWH (C) may be used in lower-risk obstetric APS but is insufficient here given triple positivity and prior late fetal loss and thrombocytopenia suggestive of high thrombotic risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with a history of recurrent pregnancy loss (two miscarriages and one fetal demise) and laboratory findings highly suggestive of antiphospholipid syndrome (APS): lupus anticoagulant, high-titer anticardiolipin IgG, and high-titer anti-β2-glycoprotein I IgG, confirmed on two occasions 12 weeks apart. She also has clinical signs consistent with APS (livedo reticularis and digital ischemia). While she has no personal history of thrombosis, the obstetric history and laboratory findings meet the criteria for obstetric APS.\n\nManagement of obstetric APS typically involves anticoagulation to reduce the risk of pregnancy complications. Low-dose aspirin is generally recommended for all pregnant women with APS to reduce the risk of preeclampsia and fetal growth restriction. However, given her history of fetal demise and recurrent pregnancy loss, a more aggressive anticoagulation strategy is warranted.\n\nTherapeutic-dose low-molecular-weight heparin (LMWH) in addition to low-dose aspirin has been shown to be effective in improving pregnancy outcomes in women with APS and a history of thrombosis or recurrent pregnancy loss. Prophylactic doses of LMWH are generally considered for women with APS and no history of thrombosis, but given her significant obstetric history, therapeutic dosing is more appropriate.\n\nLet's analyze the options:\n\nA. Low-dose aspirin alone starting preconception, escalate to prophylactic LMWH only if thrombosis occurs: This is insufficient given her history of fetal demise and positive APS markers. Waiting for thrombosis is not appropriate.\n\nB. Therapeutic-dose LMWH plus low-dose aspirin starting at positive pregnancy test and continuing 6 weeks postpartum: This is a strong contender. Starting anticoagulation at a positive pregnancy test is reasonable, and continuing postpartum is standard for women with APS. However, starting preconception might offer a slight advantage in preventing early pregnancy loss.\n\nC. Prophylactic-dose LMWH plus low-dose aspirin starting at conception and stopping at delivery: Prophylactic dose might be insufficient given her history. Stopping at delivery is also not ideal, as postpartum complications can occur.\n\nD. Low-dose aspirin only during pregnancy, with postpartum prophylactic LMWH for 6 weeks: This is insufficient during pregnancy given her history of fetal demise.\n\nE. No anticoagulation unless she develops hypertensive disorders of pregnancy: This is incorrect. Her APS diagnosis warrants anticoagulation regardless of hypertensive disorders.\n\nConsidering the evidence and guidelines for managing obstetric APS, the most appropriate plan involves both low-dose aspirin and therapeutic-dose LMWH. The timing of initiation and duration are crucial. Starting treatment preconception or very early in pregnancy is preferred to maximize the chances of a successful pregnancy. Continuing postpartum is also important.\n\nOption B suggests starting at a positive pregnancy test and continuing postpartum. While starting preconception might be ideal, a positive pregnancy test is a clear trigger for initiating treatment. Therapeutic-dose LMWH is indicated due to her history of fetal demise.\n\nLet's re-evaluate the options with a focus on the most comprehensive and evidence-based approach for this high-risk patient. The combination of aspirin and LMWH is standard. The question is about the dose and timing. Given the history of fetal demise, therapeutic-dose LMWH is generally recommended over prophylactic. Starting treatment as early as possible is also beneficial.\n\nOption B: Therapeutic-dose LMWH plus low-dose aspirin starting at positive pregnancy test and continuing 6 weeks postpartum. This is a very reasonable approach.\n\nLet's consider if starting preconception is definitively better than starting at a positive pregnancy test. Some guidelines suggest starting preconception for women with a history of thrombosis or multiple pregnancy losses. However, starting at a positive pregnancy test is also a common and effective strategy.\n\nLet's look closer at the options again. The patient has a history of recurrent pregnancy loss and confirmed APS. This is a high-risk pregnancy.\n\nOption B: Therapeutic-dose LMWH plus low-dose aspirin starting at positive pregnancy test and continuing 6 weeks postpartum. This is a strong option.\n\nLet's consider if there's a better option. The question asks for the *most* appropriate plan.\n\nIf we consider the possibility of early implantation issues or very early losses, starting preconception might be theoretically better. However, among the given options, option B provides the most robust treatment for a patient with confirmed APS and a history of fetal demise.\n\nLet's assume the question implies that starting at a positive pregnancy test is acceptable and effective. The key elements are therapeutic-dose LMWH, low-dose aspirin, and postpartum continuation.\n\nLet's re-examine the options for any subtle differences.\nOption B: Therapeutic-dose LMWH plus low-dose aspirin starting at positive pregnancy test and continuing 6 weeks postpartum.\nOption C: Prophylactic-dose LMWH plus low-dose aspirin starting at conception and stopping at delivery. This uses prophylactic dose, which is likely insufficient, and stops at delivery.\n\nComparing B and C, B is superior due to therapeutic dosing and postpartum continuation.\n\nLet's consider if starting preconception is a critical factor that makes another option better. If there were an option like \"Therapeutic-dose LMWH plus low-dose aspirin starting preconception and continuing 6 weeks postpartum,\" that might be considered even better. However, that option is not available.\n\nGiven the options, option B represents the most appropriate management plan that balances effectiveness and practicality. The use of therapeutic-dose LMWH is crucial for reducing the risk of pregnancy loss in women with APS and a history of fetal demise. Starting at a positive pregnancy test is a standard and effective time to initiate treatment. Continuing postpartum is also important.\n\nFinal consideration: The patient has livedo reticularis and digital ischemia, which are clinical manifestations of APS. This reinforces the diagnosis and the need for aggressive management.\n\nLet's assume that \"starting at positive pregnancy test\" is considered equivalent to \"starting at conception\" in terms of effectiveness for this question, as the exact timing of conception is often not precisely known, and a positive pregnancy test is the first definitive sign. The critical difference between B and C is the dose of LMWH and the duration of treatment. Therapeutic dose and postpartum continuation are more appropriate for this patient.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-009", "question": "A 55-year-old man from a region endemic for Lyme disease presents with 1 week of rapidly progressive bilateral leg weakness and numbness ascending from the feet, severe radicular pain, and new urinary retention. He was treated with oral doxycycline 3 weeks ago for erythema migrans following a hiking trip. Exam: symmetric lower extremity weakness 3/5 proximally and distally, hyperreflexia with bilateral Babinski signs, decreased pinprick below T10, preserved vibration sense in toes, and saddle hypesthesia. Cranial nerves are normal. MRI spine with contrast: multifocal enhancing lesions in the thoracic cord with associated leptomeningeal enhancement; no compressive lesion. CSF: WBC 220/µL (80% lymphocytes), protein 120 mg/dL, glucose 45 mg/dL (serum 90), oligoclonal bands present; CSF Lyme antibody index is elevated. HIV, syphilis, and TB tests are negative. What is the most appropriate treatment?", "options": ["High-dose IV methylprednisolone alone for presumed idiopathic transverse myelitis", "IV ceftriaxone 2 g daily for 4 weeks without steroids", "IV ceftriaxone 2 g daily plus high-dose IV methylprednisolone", "Oral doxycycline 100 mg BID for 28 days plus high-dose oral prednisone taper", "Plasma exchange for 5-7 sessions followed by IV ceftriaxone"], "answer": "B", "answer_index": 1, "explanation": "This is Lyme neuroborreliosis with meningomyelitis confirmed by elevated CSF Lyme antibody index and appropriate clinical picture; standard treatment is prolonged IV ceftriaxone without routine adjunctive steroids. Steroids alone (A) are inappropriate and may worsen infection. Adding high-dose steroids to antibiotics (C) has no proven benefit and may be harmful. Oral doxycycline (D) is inadequate for CNS parenchymal involvement. Plasma exchange (E) is used in severe autoimmune demyelination (e.g., NMO, ADEM) and is not indicated here once Lyme is confirmed.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with symptoms highly suggestive of neuroborreliosis, specifically a myelopathy, given the rapidly progressive bilateral leg weakness, numbness, radicular pain, urinary retention, and the presence of multifocal enhancing lesions in the thoracic cord with leptomeningeal enhancement on MRI. The CSF findings, including pleocytosis with lymphocytic predominance, elevated protein, normal glucose, and positive Lyme antibody index, further support this diagnosis. The patient's recent history of erythema migrans and travel to an endemic area strengthens the suspicion for Lyme disease.\n\nThe question asks for the most appropriate treatment. Let's analyze the options:\n\nA. High-dose IV methylprednisolone alone for presumed idiopathic transverse myelitis: While the symptoms can mimic transverse myelitis, the strong evidence for Lyme disease makes this approach inappropriate as it would not address the underlying infection and could potentially worsen it or mask its progression.\n\nB. IV ceftriaxone 2 g daily for 4 weeks without steroids: This option addresses the Lyme infection with appropriate intravenous antibiotics. However, given the severity of the neurological involvement (significant weakness, Babinski signs, sensory deficits, and leptomeningeal enhancement), a more aggressive approach might be warranted, and the role of steroids in managing inflammatory neurological complications of Lyme disease is often considered.\n\nC. IV ceftriaxone 2 g daily plus high-dose IV methylprednisolone: This option combines effective treatment for neuroborreliosis with intravenous ceftriaxone and immunosuppression with high-dose intravenous methylprednisolone. This approach is often recommended for severe neuroborreliosis with significant neurological deficits and inflammation, as it targets both the infection and the inflammatory response contributing to the neurological damage. The presence of leptomeningeal enhancement suggests significant inflammation.\n\nD. Oral doxycycline 100 mg BID for 28 days plus high-dose oral prednisone taper: Oral doxycycline is generally used for early localized Lyme disease or disseminated disease without significant neurological involvement. For neuroborreliosis, especially with myelopathy and leptomeningeal enhancement, intravenous antibiotics are preferred due to better penetration into the central nervous system. Oral steroids might be considered, but the primary antibiotic treatment should be intravenous.\n\nE. Plasma exchange for 5-7 sessions followed by IV ceftriaxone: Plasma exchange is typically reserved for conditions where antibodies play a significant pathogenic role and are not effectively managed by other means, such as certain autoimmune neuropathies. While there is inflammation, it is primarily driven by the infectious agent and the host's immune response to it, not necessarily a circulating autoantibody against myelin or nerve components in the same way as in some other neurological disorders. Therefore, plasma exchange is not the first-line treatment for neuroborreliosis.\n\nConsidering the severity of the neurological presentation and the evidence for active neuroinflammation in the context of confirmed Lyme disease, a combination of intravenous antibiotics and high-dose intravenous corticosteroids is the most appropriate treatment strategy to address both the infection and the inflammatory component of the myelopathy.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-010", "question": "A 48-year-old woman with seropositive rheumatoid arthritis (RF and anti-CCP positive) on methotrexate and adalimumab presents with subacute dyspnea and nonproductive cough. She has never smoked. Vitals: HR 104, BP 118/70, RR 22, SpO2 91% RA. Exam: fine bibasilar crackles, no wheezing, active small-joint synovitis. PFTs: FVC 58% predicted, FEV1/FVC 0.86, DLCO 35% predicted. HRCT: basilar-predominant reticulation, traction bronchiectasis, and patchy subpleural honeycombing consistent with usual interstitial pneumonia (UIP); no nodules or pleural effusions. Which of the following is the most appropriate disease-modifying management change?", "options": ["Continue methotrexate and adalimumab and add low-dose prednisone", "Discontinue methotrexate and switch adalimumab to rituximab", "Stop adalimumab and start tocilizumab while continuing methotrexate", "Continue current RA regimen and initiate mycophenolate mofetil for lung disease", "Add nintedanib while continuing methotrexate and adalimumab unchanged"], "answer": "B", "answer_index": 1, "explanation": "She has RA-associated ILD with a UIP pattern, in which methotrexate and TNF inhibitors are relatively contraindicated due to concerns for ILD progression; rituximab is preferred as an RA biologic in ILD. Continuing MTX/TNF with steroids (A) risks worsening lung fibrosis. Tocilizumab (C) has less data and does not address TNF-risk concerns. Adding mycophenolate (D) without removing potential pulmonary offenders is suboptimal. Nintedanib (E) may be beneficial in progressive fibrosing RA-ILD, but first-line is to remove MTX/TNF and choose an ILD-favorable biologic such as rituximab.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The patient presents with subacute dyspnea, cough, bibasilar crackles, and PFTs/HRCT findings consistent with interstitial lung disease (ILD), specifically UIP pattern, in the context of seropositive rheumatoid arthritis (RA) and treatment with methotrexate and adalimumab. This combination of RA and UIP is known as rheumatoid lung disease.\n\nLet's analyze the options:\n\nA. Continue methotrexate and adalimumab and add low-dose prednisone: While corticosteroids can be used in some forms of RA-ILD, the UIP pattern is generally less responsive to steroids and can even be worsened by them. Furthermore, the patient is already on immunosuppressants, and adding steroids might increase infection risk without guaranteed benefit for UIP.\n\nB. Discontinue methotrexate and switch adalimumab to rituximab: Methotrexate is a common trigger for drug-induced ILD, but the HRCT findings are more suggestive of underlying RA-ILD with a UIP pattern rather than a purely drug-induced process. Rituximab is a B-cell depleting agent and is not typically the first-line treatment for RA-ILD, especially with a UIP pattern.\n\nC. Stop adalimumab and start tocilizumab while continuing methotrexate: Tocilizumab is an IL-6 inhibitor. While it can be used for RA, its role in RA-ILD, particularly with a UIP pattern, is not as well-established as other agents. Stopping adalimumab might be considered if it were suspected as the sole cause, but the UIP pattern points to a more intrinsic lung process related to RA.\n\nD. Continue current RA regimen and initiate mycophenolate mofetil for lung disease: Mycophenolate mofetil is an immunosuppressant that can be used for various autoimmune-related ILDs. However, for RA-ILD with a UIP pattern, it is not the most evidence-based or first-line therapy.\n\nE. Add nintedanib while continuing methotrexate and adalimumab unchanged: Nintedanib is a tyrosine kinase inhibitor that has demonstrated efficacy in slowing the progression of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing ILDs with a UIP pattern, including RA-ILD. Given the UIP pattern on HRCT and the progressive nature of the disease, nintedanib is a strong candidate for management. Continuing the current RA medications is reasonable as they are treating the underlying RA, and the focus here is on managing the fibrotic lung disease.\n\nConsidering the UIP pattern on HRCT, which is a poor prognostic indicator and often associated with progressive fibrosis, nintedanib is the most appropriate disease-modifying management change to slow the progression of the lung disease.\n\nThe answer is (E)"}]